Can the skin forget psoriasis?

Treat early* with TREMFYA® to target disease memory and achieve a deep, durable response†11-3



"Although my skin is now clear, I am still scared that my psoriasis will come back"

Discover Hanna's story

Visit us at booth A23 to find out more!

Start Strong, Go Long §1,4,5

*In patients who had their first Pso symptoms ≤2 years before screening.6

Johnson&Johnson

[†]TRM cells remain in the skin even after lesions have healed, creating a disease memory; TREMFYA® has demonstrated reduction of TRM cells to levels similar to non-lesional skin.3 ‡A "deep" response comprises TRM cell reduction and complete skin clearance 1.3

[§]Strong: ECLIPSE: PASI 90 = 84% at Week 48 (n=329). Long: VOYAGE-1: PASI 90 & IGA 0/1 = 73.3% and 85.1% at Week 25 (n=391, TREMFYA® open-label at Week 52, includes patients randomised to TREMFYA® at baseline and those randomised to placebo at baseline who crossed over to receive TREMFYA® at Week 16, TFR).

IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index; TFR, treatment failure rules; TRM, tissue-resident memory T cells.

REFERENCES: **1.** Reich K, et al. *Br J Dermatol.* 2021;185:1146–1159. **2.** Mehta H, et al. *J Invest Dermatol.* 2021;185:1146–179. **3.** Eyerich K, et al. *Br J Dermatol.* 2021;185:1146–1159. **6.** Eyerich K, et al. *BMJ Open.* 2021;11(9):e049822. **7.** Cheuk S, et al. *J Immunol.* 2014;192(7):3111–3120. The Product Information for countries outside the EU may differ. Please consult your local health authorities for information. SmPC available at the booth.

Janssen Pharmaceutica N.V., a company of Johnson & Johnson in EMEA, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium CP-464935 | August 2024